CN102686611A - 与“渐进性糖化终产物受体”结合的多肽以及包括所述多肽的组合物和方法 - Google Patents

与“渐进性糖化终产物受体”结合的多肽以及包括所述多肽的组合物和方法 Download PDF

Info

Publication number
CN102686611A
CN102686611A CN201080045826XA CN201080045826A CN102686611A CN 102686611 A CN102686611 A CN 102686611A CN 201080045826X A CN201080045826X A CN 201080045826XA CN 201080045826 A CN201080045826 A CN 201080045826A CN 102686611 A CN102686611 A CN 102686611A
Authority
CN
China
Prior art keywords
seq
polypeptide
rage
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201080045826XA
Other languages
English (en)
Chinese (zh)
Inventor
J·胡贝尔
F·布朗谢
T·达布杜比
F·苏布里耶
I·弗肯
J·克鲁伊
K·赫尔梅尔
C·兰格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09290778A external-priority patent/EP2308896A1/en
Priority claimed from EP09290845A external-priority patent/EP2319871A1/en
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN102686611A publication Critical patent/CN102686611A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
CN201080045826XA 2009-10-09 2010-10-08 与“渐进性糖化终产物受体”结合的多肽以及包括所述多肽的组合物和方法 Pending CN102686611A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09290778A EP2308896A1 (en) 2009-10-09 2009-10-09 Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP09290778.1 2009-10-09
EP09290845A EP2319871A1 (en) 2009-11-05 2009-11-05 Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP09290845.8 2009-11-05
PCT/EP2010/065124 WO2011042548A1 (en) 2009-10-09 2010-10-08 Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same

Publications (1)

Publication Number Publication Date
CN102686611A true CN102686611A (zh) 2012-09-19

Family

ID=43448431

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080045826XA Pending CN102686611A (zh) 2009-10-09 2010-10-08 与“渐进性糖化终产物受体”结合的多肽以及包括所述多肽的组合物和方法

Country Status (20)

Country Link
US (1) US20120282637A1 (https=)
EP (1) EP2486058A1 (https=)
JP (1) JP2013507115A (https=)
KR (1) KR20120089863A (https=)
CN (1) CN102686611A (https=)
AU (1) AU2010305374A1 (https=)
BR (1) BR112012007821A2 (https=)
CA (1) CA2777237A1 (https=)
CL (1) CL2012000886A1 (https=)
CR (1) CR20120139A (https=)
EC (1) ECSP12011787A (https=)
IL (1) IL218968A0 (https=)
MA (1) MA33661B1 (https=)
MX (1) MX2012004090A (https=)
PE (1) PE20121689A1 (https=)
PH (1) PH12012500564A1 (https=)
RU (1) RU2558301C2 (https=)
TN (1) TN2012000138A1 (https=)
WO (1) WO2011042548A1 (https=)
ZA (1) ZA201202099B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107922499A (zh) * 2015-09-08 2018-04-17 卫材R&D管理有限公司 抗EphA4抗体
CN108570106A (zh) * 2017-03-10 2018-09-25 北京天广实生物技术股份有限公司 抗埃博拉病毒单克隆抗体、其制备方法及用途
CN114222760A (zh) * 2019-06-26 2022-03-22 葛兰素史密斯克莱知识产权发展有限公司 Il1rap结合蛋白
CN116554311A (zh) * 2023-05-04 2023-08-08 中国人民解放军军事科学院军事医学研究院 抗CD2v-N的特异性抗体及其应用

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
GB201200563D0 (en) * 2012-01-13 2012-02-29 Imp Innovations Ltd Binding molecule
WO2014167826A1 (ja) * 2013-04-08 2014-10-16 株式会社免疫生物研究所 アミロイド前駆体タンパク質のα－セクレターゼ切断後のＣ末端側断片の切断面を特異的に認識する抗体及びその利用
WO2014197460A1 (en) * 2013-06-04 2014-12-11 The Trustees Of The University Of Pennsylvania Methods for diagnosing and treating bicuspid aortic valve and/or aortopathies
CN113150145B (zh) 2013-08-30 2025-02-14 伊缪诺金公司 用于检测叶酸受体1的抗体和测定
EP3077823B1 (en) 2013-12-05 2019-09-04 The Broad Institute, Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
EP3207062A1 (en) * 2014-10-16 2017-08-23 The Broad Institute Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
JP6679096B2 (ja) * 2014-10-21 2020-04-15 学校法人 久留米大学 Ｒａｇｅアプタマーおよびその用途
US10626176B2 (en) 2014-10-31 2020-04-21 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind B7-H4
EP3294335B1 (en) * 2015-05-12 2023-07-05 Syntimmune Inc. Humanized affinity matured anti-fcrn antibodies
EP4679095A3 (en) 2015-05-18 2026-05-06 Agensys, Inc. Antibodies that bind to axl proteins
WO2016187354A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
EP3822291A1 (en) 2015-06-10 2021-05-19 The Broad Institute Inc. Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia
WO2016201319A1 (en) * 2015-06-10 2016-12-15 The Broad Institute Inc. Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia
JP6578595B2 (ja) * 2015-08-28 2019-09-25 国立研究開発法人科学技術振興機構 抗アセチル化ヒストンｈ４抗体
CN116440279B (zh) 2015-09-17 2026-02-24 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
WO2017106196A1 (en) 2015-12-14 2017-06-22 The Broad Institute, Inc. Compositions and methods for treating cardiac dysfunction
JP7262440B2 (ja) * 2017-08-02 2023-04-21 フェインズ セラピューティクス，インコーポレーテッド 抗ｃｄ４７抗体及びその使用
AU2019247511B2 (en) 2018-04-06 2025-10-16 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
US11345744B2 (en) 2019-05-07 2022-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
CA3156803A1 (en) * 2019-10-03 2021-04-08 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
WO2022019924A1 (en) * 2020-07-23 2022-01-27 Church William R Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
CN113956363B (zh) * 2021-10-13 2023-03-31 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和cd24的重组融合蛋白及其制备和用途
CN118574852A (zh) * 2021-11-18 2024-08-30 萨尔瓦瑞克斯有限责任公司 晚期糖基化终末产物受体（rage）的抗体及其用途
KR20250001879A (ko) 2023-06-28 2025-01-07 주식회사 세바바이오텍 완도호랑가시나무와 노루궁뎅이버섯 추출물을 유효성분으로 포함하는 최종당화산물 억제용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039125A1 (en) * 1996-04-16 1997-10-23 Schering Aktiengesellschaft Patente Antibodies against the advanced glycosylation end-product receptor and uses thereof
WO2007109747A2 (en) * 2006-03-21 2007-09-27 Wyeth Methods and compositions for antagonism of rage
WO2008137552A2 (en) * 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof
CN101405300A (zh) * 2006-03-21 2009-04-08 惠氏公司 用于拮抗rage的方法及组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
MY131805A (en) * 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
RU2413520C2 (ru) 2000-06-08 2011-03-10 Интерселл Аг Вакцинная композиция, содержащая иммуностимулирующие олигодезоксинуклеотиды
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
CA2418854A1 (en) 2000-08-17 2002-02-21 Jorg Fritz A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
WO2002094845A2 (en) 2001-05-21 2002-11-28 Intercell Ag Method for stabilising of nucleic acids
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
CA2645125A1 (en) * 2006-03-02 2007-09-13 Oncotherapy Science, Inc. Methods for diagnosing pancreatic cancer using reg4 protein
JP2009541275A (ja) * 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
CN100586960C (zh) * 2006-06-23 2010-02-03 陈志南 HAb18GC2单抗和其轻、重链可变区基因及应用
EP2116556B1 (en) * 2008-05-09 2016-03-23 AbbVie Deutschland GmbH & Co KG Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039125A1 (en) * 1996-04-16 1997-10-23 Schering Aktiengesellschaft Patente Antibodies against the advanced glycosylation end-product receptor and uses thereof
WO2007109747A2 (en) * 2006-03-21 2007-09-27 Wyeth Methods and compositions for antagonism of rage
CN101405300A (zh) * 2006-03-21 2009-04-08 惠氏公司 用于拮抗rage的方法及组合物
WO2008137552A2 (en) * 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
朱平 等: ""抗人晚期糖基化终产物受体胞外段不同表位单克隆抗体的制备"", 《第一军医大学学报》 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107922499A (zh) * 2015-09-08 2018-04-17 卫材R&D管理有限公司 抗EphA4抗体
CN107922499B (zh) * 2015-09-08 2021-08-27 卫材R&D管理有限公司 抗EphA4抗体
CN108570106A (zh) * 2017-03-10 2018-09-25 北京天广实生物技术股份有限公司 抗埃博拉病毒单克隆抗体、其制备方法及用途
CN108570106B (zh) * 2017-03-10 2021-07-16 北京天广实生物技术股份有限公司 抗埃博拉病毒单克隆抗体、其制备方法及用途
CN113512111A (zh) * 2017-03-10 2021-10-19 北京天广实生物技术股份有限公司 抗埃博拉病毒单克隆抗体、其制备方法及用途
CN113512111B (zh) * 2017-03-10 2023-08-15 北京天广实生物技术股份有限公司 抗埃博拉病毒单克隆抗体、其制备方法及用途
CN114222760A (zh) * 2019-06-26 2022-03-22 葛兰素史密斯克莱知识产权发展有限公司 Il1rap结合蛋白
CN116554311A (zh) * 2023-05-04 2023-08-08 中国人民解放军军事科学院军事医学研究院 抗CD2v-N的特异性抗体及其应用
CN116554311B (zh) * 2023-05-04 2023-11-21 中国人民解放军军事科学院军事医学研究院 抗CD2v-N的特异性抗体及其应用

Also Published As

Publication number Publication date
TN2012000138A1 (en) 2013-09-19
ECSP12011787A (es) 2012-10-30
RU2012118598A (ru) 2013-11-20
ZA201202099B (en) 2012-11-28
AU2010305374A1 (en) 2012-05-03
MX2012004090A (es) 2012-04-20
EP2486058A1 (en) 2012-08-15
IL218968A0 (en) 2012-07-31
CA2777237A1 (en) 2011-04-14
JP2013507115A (ja) 2013-03-04
US20120282637A1 (en) 2012-11-08
PE20121689A1 (es) 2012-12-14
BR112012007821A2 (pt) 2017-05-30
CL2012000886A1 (es) 2012-12-14
MA33661B1 (fr) 2012-10-01
CR20120139A (es) 2012-07-13
PH12012500564A1 (en) 2012-10-22
KR20120089863A (ko) 2012-08-14
WO2011042548A1 (en) 2011-04-14
RU2558301C2 (ru) 2015-07-27

Similar Documents

Publication Publication Date Title
CN102686611A (zh) 与“渐进性糖化终产物受体”结合的多肽以及包括所述多肽的组合物和方法
JP7337204B2 (ja) 単鎖可変フラグメントｃｄ３結合タンパク質
TWI767899B (zh) Psma及cd3雙特異性t細胞嚙合抗體構築體
TWI701259B (zh) ４﹘１ｂｂ抗體及其製備方法和應用
CN102459333B (zh) 抗-Tau pS422抗体用于治疗脑病的应用
JP7811315B2 (ja) 補体関連疾患のための融合タンパク質構築物
EP3689909A1 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
CN111269315B (zh) 针对bcma的单克隆抗体
TWI598361B (zh) Ｃｘ３ｃｒ１－結合多肽
WO2019157843A1 (zh) Cd47单域抗体及其用途
WO2024046239A1 (zh) 靶向人gprc5d的重组人源化单克隆抗体及其应用
AU2020281378B2 (en) Anti-TrkA antibodies and uses thereof
CN103724430A (zh) 抗mif抗体
CN104302665A (zh) 与新生儿Fc受体的结合增强的变体Fc多肽
KR102884943B1 (ko) 개선된 항-flt3 항원 결합 단백질
TW201039847A (en) Antibodies against human tweak and uses thereof
TW202409074A (zh) 鬆弛素或類似物的融合蛋白及其醫藥用途
KR20250166188A (ko) Tnfr2 결합 폴리펩타이드 및 이의 용도의 방법
TW201102086A (en) Antibodies against human CCN1 and uses thereof
CN118754989B (zh) 一种抗her2纳米抗体及其制备方法和应用
JP2026500703A (ja) 融合タンパク質
JP2007527703A (ja) 肺炎球菌表面付着因子Ａタンパク質（ＰｓａＡ）に関する結合メンバー
EP2319871A1 (en) Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP2308896A1 (en) Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
CA3111462C (en) Improved anti-flt3 antigen binding proteins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120919